Evidence map›Paper›PMID 41787225›Full record

ReviewTherapeutic innovation & regulatory science2026

Mapping the evolution of cell and gene therapy product research: trends, collaborations, and emerging frontiers.

Yanmei Rao, Li Dong, Zhe Huang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yanmei RaoSchool of Business Administration, Shenyang Pharmaceutical University, 103Wenhua Road, Shenhe District, Shenyang, 110016, China.
Li DongSchool of Business Administration, Shenyang Pharmaceutical University, 103Wenhua Road, Shenhe District, Shenyang, 110016, China. sydongli@163.com.
Zhe HuangSchool of Business Administration, Shenyang Pharmaceutical University, 103Wenhua Road, Shenhe District, Shenyang, 110016, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced therapeutic medicinal products represent a broad spectrum of biopharmaceutical innovations that prominently feature cell and gene therapy formulations. These cutting-edge therapeutic modalities are specifically engineered to intervene in and prevent illnesses that historically necessitated continuous, long-term management. To visually portray the most recent trajectories in cell and gene therapy investigations and to map out prevailing global advancements, a bibliometric assessment was conducted. This analysis meticulously sourced its data from the Web of Science Core Collection database and was significantly enhanced by analytical platforms such as VOSviewer and CiteSpace. Cell and gene therapy products demonstrate considerable promise for both foundational scientific inquiry and diverse clinical interventions, with their utility now extending far beyond cancer treatment to encompass a wide array of other pathological conditions. This paper provides a comprehensive examination of the evolving trends, collaborative endeavors, and burgeoning frontiers within the dynamic landscape of cell and gene therapy products.

Indexed as

Cell- and Tissue-Based TherapyGenetic TherapyAnimalsBibliometricsGene Therapy AgentsHumansBibliometric visualizationCancer therapyCell and gene therapy productsDiseases

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.